Applications Claiming Priority (2) Publications (3) Family ID=59224519 Family Applications (1) Country Status (7) Families Citing this family (24) Family Cites Families (10) 2015 2015-12-30 CN CN201511027176.7A patent/CN106928343A/en active Pending 2016 2016-12-16 ES ES16880981T patent/ES2809678T3/en active Active 2016-12-16 EP EP16880981.2A patent/EP3398960B1/en active Active 2016-12-16 WO PCT/CN2016/110373 patent/WO2017114191A1/en not_active Ceased 2016-12-16 JP JP2018534077A patent/JP6626210B2/en active Active 2016-12-16 HU HUE16880981A patent/HUE051531T2/en unknown 2016-12-16 US US16/067,115 patent/US20190010204A1/en not_active Abandoned
Finished dosage development may involve oral, injectable, or other permitted dosage formats depending on formulation route, market authorization, and applicable regulatory requirements
The only concern with glutathione comes when it is inserted intravenously
SUGGESTED DAILY USE: Take one (1) capsule per day without food
When selecting codes, focus on the diagnosis and clinical intent rather than the device used
The weight loss data confirm that continued treatment beyond 48 weeks produces additional weight reduction: The 28.7% at 68 weeks exceeds the 24.2% at 48 weeks from Phase 2, representing approximately 4.5 additional percentage points of weight loss over the additional 20 weeks of treatment